[Merck’s ADC drug reduces the risk of death in patients with advanced endometrial cancer by 32%] On October 26, Merck announced the results of the phase III TroFuse-005 clinical trial of its ongoing TROP2-targeted antibody conjugate (ADC) sacituzumab. Compared with chemotherapy, tirumotecan (sac-TMT) reduces the risk of death by 32% and the risk of disease progression or death by 41% in patients with advanced or recurrent endometrial cancer who have previously received platinum-based chemotherapy and anti-PD-1/L1 immunotherapy. The median overall survival was 19.0 months, 6.9 months longer than the 12.1 months in the chemotherapy group; the median progression-free survival was 7.2 months, 3.3 months longer than the 3.9 months in the chemotherapy group. The objective response rate was 35.1%, which was higher than the 17.3% in the chemotherapy group. The study included 776 patients. The U.S. FDA has accepted the drug's biologics license application for relevant patient groups and granted priority review, with a target decision date of June 15, 2027.